Biomarkers discovered for inflammatory bowel disease
Mayo Clinic researchers found that having the intestine-inflaming condition ups risk of heart attack and stroke by 10 to 25 percent. The findings are based on data from 150,000 people with the condition who were included in nine studies, and were presented at the annual meeting of the American College of Gastroenterology earlier this month. "Gastroenterologists should be cognizant of this relationship and should focus on better management of conventional risk factors , such as smoking cessation, recognition and control of hypertension and diabetes," study researcher Siddharth Singh, M.B.B.S., said in a statement. Inflammatory bowel disease first appears most often between the ages of 15 and 30 , with about one in 10 cases appearing before a person turns 18, according to the Centers for Disease Control and Prevention. While data on the prevalence of the condition is not strong due to factors such as misdiagnosis, the CDC noted that up to 1.4 million people in the U.S. are affected by it. However, the costs of the condition are known, costing more than $1.7 billion overall. Contribute to this Story:
The main types of IBD are Crohn's disease and ulcerative colitis; inflammatory bowel diseases are considered autoimmune diseases in which the body's own immune system attacks elements of the digestive system. In this study, researchers used the repository to identify 50 cases of Crohn's disease and 50 cases of ulcerative colitis. They analyzed proteins from three samples per casetwo taken before and one after diagnosisusing a statistical analysis format. Certain proteins were found in elevated levels in samples from patients who developed IBD. "The selection of proteins we chose to analyze was based on a prior study conducted at UC," Yacyshyn says. "Although the presence of proteins in those who develop Crohn's disease varies from those present in ulcerative colitis patients, we were able to show that there were elevated levels of certain proteins in patients who developed IBD." "Future large validation studies are needed to confirm the presence of biomarkers to guide in diagnosis, prevention and management of these patients," he adds.